Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.51 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18222559 | 0.90 | PTGDR2 (0.53) | PTGDR2SPRPTGDRMAPTPOLB | |
| SCHEMBL18222512 | 0.88 | PTGDR2 (0.51) | PTGDR2SPRPTGDRMAPTPOLB | |
| SCHEMBL18239786 | 0.87 | HTR6 (0.56) | PTGDR2PTGDRMAPTPOLBHTR6 | |
| SCHEMBL28100912 | 0.80 | SPR (0.45) | PTGDR2SPRPTGDRMAPTHTR6 | |
| SCHEMBL18239836 | 0.79 | HTR6 (0.43) | PTGDR2PTGDRMAPTPOLBMEN1 | |
| SCHEMBL28100773 | 0.79 | SPR (0.48) | PTGDR2SPRPTGDRMAPTHTR6 | |
| SCHEMBL18239791 | 0.78 | PTGDR2 (0.40) | PTGDR2PTGDRMAPTPOLBHTR6 | |
| SCHEMBL18239754 | 0.77 | HTR6 (0.57) | PTGDR2PTGDRPOLBHTR6KDM4E | |
| SCHEMBL18800024 | 0.75 | SPR (0.50) | SPRMAPTKDM4EGAA | |
| SCHEMBL18222517 | 0.75 | HTR6 (0.56) | PTGDR2PTGDRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637451-B2 | Indole compound | ASTELLAS PHARMA INC. (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-3095781-A1 | INDOLE COMPOUND | Astellas Pharma Inc. (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-20160332966-A1 | INDOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332966-A1 | INDOLE COMPOUND | MTNR1A, MTNR1B, IDO2 | PTGDR2 86/4885SPR 698/4885PTGDR 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.